Incidence and Market
Alzheimer´s Disease will be one of the biggest burdens of the future society showing dramatic incidence rates: every 70 seconds someone in the US develops Alzheimer´s Disease, by mid-century someone will develop Alzheimer´s Disease every 33 seconds. In 2010 5.4 million people are affected by the condition in the US alone, and more than 35 million people worldwide. In the US Alzheimer´s Disease is now the 6th leading cause of death across all ages. It was the fifth leading cause of death for those aged 65 and older. Since the incidence and prevalence of Alzheimer´s Disease increase with age, the number of patients will grow dramatically with our society getting older. By 2050 we need to expect that patient numbers have tripled to 116 million Alzheimer´s Disease patients worldwide.
Market and Economic Impact
The Alzheimer´s Disease market is currently estimated at $ 5 billion annually with projections that show the market potential will surpass $ 20 billion by 2020.
The global economic impact of Alzheimer´s Disease is shown by the worldwide cost of $ 640 billion, which exceeds 1% of gross world product. It can be seen as the most significant health crisis in the 21st century.
The 2010 annual costs of treating and caring for patients was $183 billion in the U.S. alone. This figure is expected to increase to $ 1.1 trillion in 2015. Alzheimer´s Disease is becoming the third most expensive disease counting for 30% of the US healthcare costs. The medical costs for Alzheimer´s Disease patients are three times higher than for other older patients. There is also a big financial impact for the individuals and their families as the out-of-pocket-costs for the Alzheimer´s Disease patients are higher than for any other disease. As expenses for assisted living or nursing homes can often not be afforded, 70% of Alzheimer´s Disease patients live at home resulting in high impact of family’s health, emotional well-being as well as their employment and financial security.
Cost of Treatment
Currently there is no disease-modifying treatment for the Alzheimer´s Disease on the market. The disease usually is diagnosed late when already 70% of the nerve cells in the brain are dead. Several high-impact nutritional and supplementary treatment products are being developed and should particularly impact on prevention. Five drugs are approved and marketed which treat the symptoms. Better understanding of the underlying biology will lead to several new axes of treatment in different stages of clinical testing. The impact of a disease-modifying treatment can be huge: Delaying the onset of Alzheimer´s Disease by 5 years starting 2015 could result in a prevalence reduced by 5.9 million (43%) in 2050 in the US alone. Expressed in money, a delay of onset of 5 years would could result in savings of $ 447 billion of the total expected costs of $ 1.078 billion in the US alone.
2011 Alzheimer´s Disease Facts and Figures, Alzheimer´s Association
2010 Alzheimer´s Disease Facts and Figures, Alzheimer´s Association
2010 World Alzheimer´s Report, Alzheimer´s Society
Forecasting the burden of AD, 2007, Johns Hopkins University
- 2012- US PhRMA- Researching Alzheimer's Medicines: Stebacks and Stepping Stones
- 2011 World Alzheimer Report - The benefits of early diagnosis and intervention - Executive Summary
- 2011 World Alzheimer Report - The benefits of early diagnosis and intervention
- 2011 Alzheimer´s Disease Facts and Figures
- 2010 Alzheimer Report - The global Economic Impact of Dementia - Executive Summary
- 2010 Alzheimer Report - The global Economic Impact of Dementia
- Changing the Trajectory of AD: A National Imperative - Alzheimer´s Association